Hostname: page-component-848d4c4894-4hhp2 Total loading time: 0 Render date: 2024-05-10T17:07:31.142Z Has data issue: false hasContentIssue false
  • English
  • Français

Amphotericin—How Safe and Effective?

Published online by Cambridge University Press:  02 January 2015

Sandra M. Norris
Sandra M. Norris*
Affiliation:
Department of Medicine, University of Virginia Medical Center, School of Medicine, Charlottesville, Virginia
*
School of Medicine, University of Virginia, Charlottesville, VA 22908
Get access Rights & Permissions [Opens in a new window]

Extract

Over a period of 35 days beginning July 23, 1984, the Infection Control Section of the Nassau Hospital, a 535-bed community teaching institution received reports of an unusually high number of PPD tuberculin skin test conversions among employees from Employee Health Service personnel.

The first case involved a registered nurse who, upon receiving a routine annual Mantoux skin test on July 23, converted from the previous year's negative reaction to a significant reaction (20 mm induration) with a greater than normal area of erythema. When she reported this to her private medical doctor prior to beginning INH prophylaxis, she was retested by the physician. This test was read as nonreactive.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 6 , Issue 6 , June 1985 , pp. 243 - 245
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1985

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.De Gregorio, MW, Lee, WMF, Linker, CA, et al: Fungal infections in patients with acute leukemia. Am J Med 1982; 73:543–548.CrossRefGoogle ScholarPubMed
2.Butler, WT, Bennett, JE, Alling, DW, et al: Nephrotoxicity of amphotericin B. Early and late effects in 81 patients. Ann Intern Med 1964; 61:175–187.CrossRefGoogle ScholarPubMed
3.Hermans, PE, Keys, TF: Antifungal agents used for deep-seated mycotic infections. Mayo Clin Proc 1983; 58:223–231.Google ScholarPubMed
4.Graybill, JR, Craven, PC: Antifungal agents used in systemic mycoses: Activity and therapeutic use. Drugs 1983; 25:41–62.CrossRefGoogle ScholarPubMed
5.Drutz, DJ, Lehrer, RI: Development of amphotericin B-resistant Candida tropicalis in a patient with defective leukocyte function. Am J Med Sci 1978; 276:77–92.CrossRefGoogle Scholar
6.Merz, WG, Sandford, GR: Isolation and characterization of a polyene-resistant variant of Candida tropicalis. J Clin Microbiol 1979; 9:677–680.CrossRefGoogle ScholarPubMed
7.Pappagianis, D, Collins, MS, Hector, R, et al: Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob Agent Chemother 1979; 16:123–126.CrossRefGoogle ScholarPubMed
8.Dick, JD, Merz, WG, Sarai, R: Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother 1980; 18:158–163.CrossRefGoogle ScholarPubMed
9.Edwards, JE, Morrison, J, Henderson, DK, et al: Combined effects of amphotericin B and rifampin on Candida species. Antimicrob Agents Chemother 1980; 17:484–487.CrossRefGoogle ScholarPubMed
10.Kitahara, M, Seth, UK, Medoff, G, et al: Activity of amphotericin B, 5-fluorocytosine and rifampin against six clinical isolates of Aspergillus. Antimicrob Agents Chemother 1976; 9:915–919.CrossRefGoogle ScholarPubMed
11.Kobayashi, GS, Medoff, G, Schlessinger, D, et al: Amphotericin B potentiation of rifampicin as an antifungal agent against the yeast phase of Histoplasma capsulatum. Science 1972; 177:709–710.CrossRefGoogle Scholar
12.Fujita, NK, Edwards, JE: Combined in vitro effect of amphotericin B and rifampin on Cryptococcus neoformans. Antimicrob Agents Chemother 1981; 19:196–198.CrossRefGoogle ScholarPubMed
13.Kitahara, M, Kobayashi, GS, Medoff, G: Enhanced efficacy of amphotericin B and rifampicin in treatment of murine histoplasmosis and blastomycosis. J Infect Dis 1976; 133:663–668.CrossRefGoogle ScholarPubMed
14.Arroyo, J, Medoff, G, Kobayashi, GS: Therapy of murine aspergillosis with amphotericin B in combination with rifampin or 5-fluorocytosine. Antimicrob Agents Chemother 1977; 11:21–25.CrossRefGoogle ScholarPubMed
15.Lew, M, Beckett, KM, Levin, MJ: Combined activity of minocycline and amphotericin B in vitro against medically important yeasts. Antimicrob Agents Chemother 1978; 14:465–469.CrossRefGoogle ScholarPubMed
16.Medoff, G, Comfort, M, Kobayashi, GS: Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms. Proc Soc Exp Biol Med 1971; 138:571–574.CrossRefGoogle ScholarPubMed
17.Bennett, JE, Dismukes, WE, Duma, RJ, et al: A collaborative study comparing amphotericin B-5-fluorocytosine versus amphotericin B alone in the treatment of cryptococcal meningitis. N Engl J Med 1979; 301:126–131.CrossRefGoogle Scholar
18.Sud, IJ, Feingold, DS: Effect of ketoconazole on the fungicidal action of amphotericin B in Candida albicans. Antimicrob Agents Chemother 1983; 23:185–187.CrossRefGoogle ScholarPubMed
19.Polak, A, Scholer, HJ, Wall, M: Combination therapy of experimental candidiasis and aspergillosis in mice. Chemotherapy 1982; 28:461–479.CrossRefGoogle ScholarPubMed
20.Graybill, JR, Williams, DM, Cutsem, EV, et al: Combination therapy of experimental histoplasmosis and Cryptococcus with amphotericin B and ketoconazole. Rev Infect Dis 1980; 2:551–558CrossRefGoogle ScholarPubMed
21.Bindschadler, DD, Bennett, JE: A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis 1969; 120:427–436.CrossRefGoogle Scholar
22.Fisher, JF, Taylor, AT, Clark, J, et al: Penetration of amphotericin B into the human eye. J Infect Dis 1983; 147:164.CrossRefGoogle ScholarPubMed
23.Atkinson, AJ, Bennett, JE: Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 1978; 13:271–276.CrossRefGoogle ScholarPubMed
24.Craven, PC, Ludden, TM, Drutz, DJ, et al: Excretion pathways of amphotericin B. J Infect Dis 1979; 140:329–341.CrossRefGoogle ScholarPubMed
25.Morgan, DJ, Ching, MS, Raymond, K, et al: Elimination of amphotericin B in impaired renal function. Clin Pharmacol Ther 1983; 34:248–253.CrossRefGoogle ScholarPubMed
26.Block, ER, Bennett, JE, Livoti, LG, et al: Flucytosine and amphotericin B: Hemodialysis effects on the plasma concentration and clearance. Ann Intern Med 1974; 80:613–617.CrossRefGoogle ScholarPubMed
27.Bennett, WM, Aronoff, GR, Morrison, G, et al: Drug prescribing in renal failure: Dosing guidelines for adults. Am J Kidney Dis 1983; 3:155–193.CrossRefGoogle ScholarPubMed
28.Tynes, BJ, Utz, JP, Bennett, JE, et al: Reducing amphotericin B reactions: A double-blind study. Am Rev Respir Dis 1963; 87:264–268.Google ScholarPubMed
29.Utz, JP, Bennett, JE, Brandriss, MW, et al: Amphotericin B toxicity. Ann Intern Med 1964; 61:334–354.CrossRefGoogle ScholarPubMed
30.Heidemann, HT, Gerkens, JF, Spickard, WA, et al: Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983; 75:476–481.CrossRefGoogle ScholarPubMed
31.MacGregor, RR, Bennett, JE, Erslev, AJ: Erythropoietin concentration in amphotericin B-induced anemia. Antimicrob Agents Chemother 1978; 14:270–273.CrossRefGoogle ScholarPubMed
32.McCurdy, DK, Frederic, M, Elkinton, JR: Renal acidosis due to amphotericin B. N Engl J Med 1968; 278:124–131.CrossRefGoogle ScholarPubMed
33.Drutz, DJ, Fan, JH, Tai, TY, et al: Hypokalemic rhabdomyolysis and myoglobinuria following amphotericin B therapy. JAMA 1970; 211:824–826.CrossRefGoogle ScholarPubMed
34.McChesney, JA, Marquardt, JF: Hypokalemic paralysis induced by amphotericin B. JAMA 1964; 189:1029–1031.CrossRefGoogle ScholarPubMed
35.Dana, BW, Dorie, BGM, White, RF, et al: Concomitant administration of granulocyte transfusions and amphotericin B in neutropenic patients: Absence of significant pulmonary toxicity. Blood 1981; 57:90–94.CrossRefGoogle ScholarPubMed
36.DeGregorio, MW, Lee, WMF, Ries, CA: Pulmonary reactions associated with amphotericin B and leukocyte transfusions. N Engl J Med 1981; 305:585.Google Scholar
37.Forman, SJ, Robinson, GV, Wolf, JL, et al: Pulmonary reactions associated with amphotericin B and leukocyte transfusions. M Engl J Med 1981; 305:584–585.Google Scholar
38.Wright, DG, Robichaud, KJ, Pizzo, PA, et al: Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med 1981; 304:1185–1189.CrossRefGoogle ScholarPubMed
39.Bennett, JE: Antifungal agents, in Mandell, GL, Douglas, RG Jr, Bennett, JE (eds): Principles and Practice of Infectious Diseases, ed 2. New York, John Wiley and Sons, 1984, pp 263–270.Google Scholar
40.Graybill, JR, Craven, PC: Antifungal agents used in systemic mycoses-Activity and therapeutic use. Drugs 1983; 25:41–62.CrossRefGoogle ScholarPubMed
41.Drutz, DJ: Therapy of fungal infections. Bull NY Acad Med 1982; 58:721–732.Google ScholarPubMed
42.Tipple, M, Shadomy, S, Espinel-Ingroff A: Availability of active amphotericin B after filtration through membrane filters. Am Rev Respir Dis 1977; 115:879–881.Google Scholar
43.Block, ER, Bennett, JE: Stability of amphotericin B in the infusion bottle. Antimicrob Agents Chemother 1973; 4:648–649.CrossRefGoogle Scholar
44.Wise, GJ, Wainstein, S, Goldberg, P, et al: Candida cystitis. Management by continuous bladder irrigation with amphotericin B. JAMA 1973; 224:1636–1637.CrossRefGoogle ScholarPubMed
45.Utz, JP: Chemotherapy of the systemic mycoses. Med Clin North Am 1982;66:221–233.CrossRefGoogle ScholarPubMed
46.Carnevale, NT, Galgiani, JN, Stevens, DA, et al: Amphotericin B-induced myelopathy. Arch Intern Med 1980; 140:1189–1192.CrossRefGoogle ScholarPubMed
47.Keane, JR: Cisternal puncture complications. Treatment of coccidioidal meningitis with amphotericin B. California Medicine 1973; 119:10–15.Google ScholarPubMed
48.Diamond, RD, Bennett, JE: A subcutaneous reservoir for intrathecal therapy of fungal meningitis. N Engl J Med 1973; 288:186–188.CrossRefGoogle ScholarPubMed